Results 51 to 60 of about 73,761 (306)

A new immunosuppressant: tacrolimus [PDF]

Postgraduate Medical Journal, 1996
Summary Tacrolimus is the new name for the Japanese immunosuppressant drug FK506. It blocks interleukin 2 transcription thereby inhibiting the CD4 Th-1 lymphocyte response to foreign antigens. It also selectively inhibits cytokine secretion of IL3, IL4 and interferon-gamma. It is metabolised by the cytochrome P-450 enzyme system.
openaire   +3 more sources

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

American Journal of Hematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley   +1 more source

Tacrolimus-Associated Dilated Cardiomyopathy in Adult Patient After Orthotopic Liver Transplant

Journal of Investigative Medicine High Impact Case Reports, 2017
This report presents a case of tacrolimus cardiotoxicity in an adult patient who received tacrolimus immunosuppression for orthotopic liver transplant (OLT).
Jennifer McLeod MD, Stephanie Wu MD, Luanda Grazette MD, Anna Sarcon MD   +3 more
doaj   +1 more source

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

Pharmaceutics, 2023
Elexacaftor/tezacaftor/ivacaftor (ETI) treatment has potential benefits in lung transplant recipients, including improvements in extrapulmonary manifestations, such as gastrointestinal and sinus disease; however, ivacaftor is an inhibitor of cytochrome ...
Eunjin Hong, Eugeniu Carmanov, Alan Shi, Peter S. Chung, Adupa P. Rao, Kevin Forrester, Paul M. Beringer   +6 more
doaj   +1 more source

An interaction between tacrolimus and pristinamycin resulting in an elevated tacrolimus level [PDF]

Clinical Kidney Journal, 2011
We report a case of interaction between tacrolimus and pristinamycin. A 62-year-old man, Mr TM, presented with a 2-day history of increased pain and left knee swelling after a twisting injury. This occurred 1 year after renal transplantation for end-stage kidney disease from membranous glomerulonephropathy, complicated by an episode of acute rejection ...
Tehan, JV, Tan, S-J, Gregg, W, Dwyer, K
openaire   +4 more sources

Astaxanthin ameliorates benzalkonium chloride–induced dry eye disease through suppressing inflammation and oxidative stress via Keap1‐Nrf2/HO‐1 signaling pathways

Animal Models and Experimental Medicine, EarlyView.
The flowchart of this research. Abstract Background Dry eye disease (DED) predominantly results from elevated tear film osmolarity, which can not only cause ocular inconvenience but may lead to visual impairments, severely compromising patient well‐being and exerting substantial economic burdens as well.
Ziyu Liu, Yaqiong Li, Jiayu Bao, Siyuan Li, Ya Wen, Peng Zhang, Jun Feng, Yinghui Wang, Lei Tian, Ying Jie   +9 more
wiley   +1 more source

Tacrolimus‐Related Neurotoxicity of the Pons in Children: Review of the Literature and a Case Report

Annals of the Child Neurology Society
Introduction Tacrolimus is a potent immunosuppressive agent effective in preventing solid organ transplant rejection. It is widely used following allogeneic liver, kidney, heart, and bone marrow transplantation.
Amy Hill, Mohamed Bilal Haradwala, Jean‐Baptiste Le Pichon   +2 more
doaj   +1 more source

Analysis of the histology of the scar bladder and biochemical parameters of rats with a solitary kidney undergoing immunosuppression with tacrolimus [PDF]

Acta Cirúrgica Brasileira, 2014
PURPOSE:To evaluate bladder histology in healing and biochemical analysis of rats with single kidney in ischemia/reperfusion, treated with tacrolimus.METHODS: Fifty rats randomized into five groups.
Ricardo Cavalheiro Cavalli, Renato Tambara Filho, Regina de Paula Xavier Gomes, Djanira Aparecida da Luz Veronez, Julio Slongo, Rogério de Fraga   +5 more
doaj   +1 more source

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal, Ingrid E. Lundberg, Yeong‐Wook Song, Aziz Shaibani, Victoria P. Werth, Michael A. Maldonado   +5 more
wiley   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source